dactinomycin has been researched along with Vasculitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahm, JB; Felix, SB; Jantzen, F; Landsberger, M; Rosenstengel, C; Staudt, A; Vogelgesang, D; Wolff, B | 1 |
| Arita, H; Nakano, T; Ohara, O; Teraoka, H | 1 |
2 other study(ies) available for dactinomycin and Vasculitis
| Article | Year |
|---|---|
Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells.
Topics: Cells, Cultured; Cytoplasm; Dactinomycin; Endothelial Cells; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Proteins; Intercellular Adhesion Molecule-1; Membrane Proteins; NF-KappaB Inhibitor alpha; Nucleic Acid Synthesis Inhibitors; Pyridines; RNA, Messenger; Simvastatin; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1; Vasculitis | 2007 |
Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Aorta, Thoracic; Bucladesine; Cells, Cultured; Colforsin; Cyclic AMP; Dactinomycin; Drug Synergism; Gene Expression; Interleukin-1; Lipopolysaccharides; Male; Muscle, Smooth, Vascular; Phospholipases; Phospholipases A; Phospholipases A2; Rats; Rats, Inbred Strains; RNA, Messenger; Tumor Necrosis Factor-alpha; Vasculitis | 1990 |